Semaglutide, known commercially as Ozempic, is a groundbreaking medication approved by the FDA for weight loss
Individual response varies due to genetic differences in receptor expression, baseline metabolic characteristics, pancreatic beta cell function, duration of diabetes, lifestyle factors, and adherence to dietary and physical activity recommendations
Mounjaro, in particular, has shown promising results, with patients achieving up to 26.6% weight loss over 84 weeks
Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, et al
reported that in an IRI mouse model, CEUS-measured renal perfusion significantly decreased after one hour and was negatively correlated with renal function recovery [143]
That blanket approach was later loosened